References
- Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24. https://doi.org/10.1200/JCO.20.1.110
- Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22: 3238-47. https://doi.org/10.1200/JCO.2004.11.057
- Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol 2006;1:1040-1. https://doi.org/10.1097/01243894-200611000-00020
- Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23:65-6. https://doi.org/10.1097/IOP.0b013e31802d9802
- Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004;151:1111-2. https://doi.org/10.1111/j.1365-2133.2004.06265.x
- Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-74. https://doi.org/10.1200/JCO.2005.04.057
- Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-2. https://doi.org/10.1200/JCO.2008.16.9391
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1711-2.
- Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76. https://doi.org/10.1046/j.1365-2133.2001.04226.x
- Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from nonsmall cell lung cancer. J Thorac Oncol 2009;4:684-8. https://doi.org/10.1097/JTO.0b013e3181a52359
Cited by
- Erlotinib : Trichomegaly of the eyelashes: case report vol.1445, pp.1, 2013, https://doi.org/10.1007/s40278-013-2202-2
- Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review vol.10, pp.2, 2015, https://doi.org/10.3892/ol.2015.3265